Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR

July 23, 2026 1:47 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: *Based on (i) 11,304,697 shares of common stock of the issuer (the "Common Stock") outstanding as of May 12, 2026, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 and (ii) the sale of an additional 1,454,175 shares of Common Stock as reported by the issuer in its Current Report on Form 8-K filed May 14, 2026.


SCHEDULE 13G



Thomas A. Satterfield, Jr.
Signature:/s/ Thomas A. Satterfield, Jr.
Name/Title:Thomas A. Satterfield, Jr.
Date:07/23/2026

Categories

SEC Filings